trending Market Intelligence /marketintelligence/en/news-insights/trending/xuwzh50xwmxxjcuh2y-gqa2 content esgSubNav
In This List

Clinuvel to appeal UK decision against reimbursing skin disease drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Clinuvel to appeal UK decision against reimbursing skin disease drug

Clinuvel Pharmaceuticals Ltd. plans to appeal the U.K.'s decision to not grant reimbursement for its skin disease drug, Scenesse.

The U.K.'s National Institute for Health and Care Excellence maintained its position against granting the drug reimbursement under the national health service, following an initial rejection in December 2017.

The final recommendation by NICE's Highly Specialised Technologies Evaluation Committee maintained that Scenesse, or afamelanotide, did not meet its health economic criteria for reimbursement.

The Australian biopharmaceutical company focuses on developing treatments for patients with a range of severe genetic and skin disorders.